New drug zorevunersen significantly reduces seizures in children with Dravet Syndrome

A new drug, zorevunersen, has shown a 91% reduction in seizures for children with rare Dravet Syndrome in an international trial. The investigational treatment boosts protein production from a healthy gene copy, offering hope for drug-resistant epilepsy. Eighty-one children participated in the phase 2 trial. This breakthrough highlights the need for increased rare disease research and treatment access in India, where epilepsy affects millions of children.